Tempus AI (TEM) Rallies +35.5% in 30 Days: Short Squeeze and Merck Tie-Up Fuel the Move
Key Takeaways
- Tempus AI (TEM) climbed roughly 35.5% over the trailing 30 days, from about $51.64 to $69.97 on a closing basis.
- The advance was amplified by a technical short squeeze tied to positive third-party precision-medicine news and an expanded AI collaboration with Merck.
- Over the last quarter, TEM has risen approximately 37.6%, recovering sharply after touching a 52-week low near $40.77 in late July.
- Second-quarter 2026 revenue grew 22% year over year, led by the Diagnostics and Data & Apps segments.
- Analyst consensus on TEM remains a Buy, though the stock now trades near or above the average 12-month price target.
Tempus AI's Business and Market Standing
Tempus AI, Inc. is a healthcare technology company that applies artificial intelligence and machine learning to precision medicine. Founded in 2015 and headquartered in Chicago, the company operates a closed-loop platform that connects laboratory diagnostics, an analytics engine, and a repository of multimodal clinical and molecular data. Its offerings span genomic and molecular diagnostics, the Hub clinical application for physicians, the Lens software platform for life sciences research, and data-licensing products under the Insights brand, with applications across oncology, cardiology, neuropsychiatry, radiology, and infectious disease.
Tempus went public on the Nasdaq in June 2024, and investors follow the stock closely because of its rapid revenue growth, its expanding data moat, and a pipeline of AI-enabled diagnostic tools and pharmaceutical collaborations. Strategic relationships include partnerships with major life-sciences and pharmaceutical companies, reinforcing its position at the intersection of healthcare data and AI. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
TEM's Price Moves: 30-Day Surge and Quarterly Recovery
Over the trailing 30 days, TEM has advanced approximately 35.5%, moving from a closing price near $51.64 to $69.97. The move was not linear: shares surged sharply in mid-August, pulled back in late August and early September, and then regained momentum into mid-September.
The broader quarterly trend tells a similar story of volatility followed by recovery. Roughly three months earlier, shares traded near $50.84. After sliding to a 52-week low around $40.77 in late July, the stock reversed powerfully, ultimately gaining about 37.6% over the full quarter. This "V-shaped" pattern reflects both a period of selling pressure and a rapid re-rating driven by catalysts discussed below.
Key Drivers Behind the Recent 30-Day Advance
The most dramatic catalyst came in mid-August, when a third-party clinical breakthrough in cancer-vaccine research triggered a broad rally across precision-medicine names. Tempus, which provides genomic testing and data infrastructure relevant to personalized oncology, was a notable beneficiary, and heavy short interest amplified the move into a technical short squeeze that lifted shares sharply over several sessions.
Around the same period, Tempus expanded its AI-driven precision-medicine partnership with Merck (MRK), reinforcing investor confidence in its pharmaceutical collaboration pipeline. The company also received FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled software device that detects signs of pulmonary hypertension from standard 12-lead electrocardiograms, and announced up to $9.5 million in ARPA-H funding to deploy autonomous AI in cardiology.
Analyst activity added further support. Personalis (PSNL) acquisition prospects prompted upgrades and price-target increases, including an Overweight initiation from Cantor Fitzgerald and an upgrade to Overweight from Piper Sandler, alongside higher targets from H.C. Wainwright. Together, these developments lifted sentiment and drove the stock's 30-day advance.
Factors Shaping Performance Over the Quarter
The quarter's trajectory was shaped first by a drawdown and then by a decisive reversal. Through late July, shares came under pressure, dipping to a 52-week low near $40.77 as growth-oriented healthcare names faced broad selling. The turning point arrived with second-quarter earnings, when Tempus reported 22% year-over-year revenue growth led by its Diagnostics and Data & Apps businesses, reinforcing the company's ability to scale despite ongoing net losses.
From there, the narrative shifted toward expansion. The pending Personalis acquisition, new FDA clearances, the Merck collaboration, and a steady stream of analyst initiations and upgrades underpinned a multi-month re-rating. The result was a quarter defined by a sharp recovery and renewed investor interest in Tempus as a leading AI-enabled precision-medicine platform.
What Could Influence TEM Next
Looking ahead, several factors could influence TEM's trajectory. Quarterly earnings remain the primary event, with the next report expected in early November 2026; investors will watch revenue growth, margins, and guidance for the Diagnostics and Data & Apps segments. Progress on the pending Personalis acquisition, including regulatory and shareholder approvals, is another key milestone.
Broader catalysts include further FDA clearances for AI-enabled diagnostic devices, new or expanded pharmaceutical and data-licensing partnerships, and developments in the competitive precision-medicine landscape. Macroeconomic conditions, interest-rate expectations, and sentiment toward high-growth, higher-beta healthcare technology names will also matter, given TEM's historically elevated volatility. As always, these are factors to monitor rather than predictions of future performance. From what I see, I’m watching this closely as the next earnings cycle approaches.
Tracking Automated Strategies with Tickeron
One resource I turn to when evaluating data-driven approaches for names like this is Tickeron’s Trending AI Robots. The page highlights a selection of AI trading bots that monitor thousands of tickers, focusing on those showing strong recent performance across different strategies and timeframes. It offers a practical way to compare automated options without sifting through every available bot.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TEM sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for TEM moved above the 200-day moving average on September 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 15, 2026. You may want to consider a long position or call options on TEM as a result. In 27 of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
TEM moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TEM crossed bullishly above the 50-day moving average on August 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +12.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in 108 of 123 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 48 of 54 cases where TEM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Bearish Trend Analysis
The 10-day RSI Indicator for TEM moved out of overbought territory on August 24, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator moved out of overbought territory. In 13 of the 13 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for TEM turned negative on September 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In 19 of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TEM broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (28.571) is slightly higher than the industry average of (7.463). P/E Ratio (39.298) is within average values for comparable stocks, (44.990). TEM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.509). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (8.696) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement